CADTH Canadian Drug Expert Committee recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication: in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF) and urgent HF visit
The CADTH Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin (Forxiga) should be reimbursed as an adjunct to standard of care therapy, for the treatment of HFrEF only if certain conditions are met
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, January 6, 2021
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin (Forxiga) should be reimbursed as an adjunct to standard of care therapy, for the treatment of HFrEF only if certain conditions are met |
---|---|
Physical Description: | 1 PDF file (7 pages) |